Quantcast

Latest Peptides Stories

2010-05-25 08:30:00

BASKING RIDGE, N.J., May 25 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, today announced issuance of another key patent related to their proprietary technology. This new patent includes coverage for RB007, the modulator or active control component of Regado's innovative product candidates, the REG1 and REG2 anticoagulation systems. The allowed claims in U.S. Patent No. 7,723,315 broadly...

2010-05-11 08:03:00

CRANBURY, N.J., May 11 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) will announce its third quarter, fiscal year 2010 financial results on Thursday, May 13, 2010 before the open of the U.S. financial markets. Palatin will also conduct a conference call and live audio webcast hosted by its executive management team on May 13, 2010, which will include discussion of the results of operations in greater detail and an update on corporate developments. Schedule for the...

2010-05-04 06:30:00

CRANBURY, N.J., May 4 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) announced that the U.S. Patent and Trademark Office issued U.S. Patent No. 7,709,484, titled "Substituted Melanocortin Receptor-Specific Piperazine Compounds," today. The claims in the issued patent relate to small molecule compounds which bind to melanocortin receptors. Palatin has received Notices of Allowance from the U.S. Patent and Trademark Office on four additional patent applications relating to...

2010-05-03 10:37:00

Preliminary review suggests an increase in the risk of diabetes and certain cardiovascular diseases in men treated with GnRH agonists SILVER SPRING, Md., May 3 /PRNewswire-USNewswire/ -- Gonadotropin-Releasing Hormone (GnRH) agonists, a class of medications primarily used to treat men with prostate cancer, have been associated with a small increased risk for diabetes, heart attack, stroke, and sudden death in men treated with one of the medications, according to a preliminary and ongoing...

2010-04-30 08:30:00

BASKING RIDGE, N.J., April 30 /PRNewswire/ -- Regado Biosciences, a privately held company leading the development of antithrombotic aptamers with active control agents, announced today that Ellen McDonald, MBA, Senior Vice President and Chief Business Officer, will be presenting at the BIO International Convention at McCormick Place in Chicago, Illinois. Ms. McDonald's presentation, scheduled on May 5, 2010 will begin at 3:30pm, CDT and will include an overview of the Company's pipeline...

2010-04-09 08:30:00

BASKING RIDGE, N.J., April 9 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Steven Zelenkofske, DO, FACC, Senior Vice President, Chief Medical Officer, presented an abstract at the Arteriosclerosis, Thrombosis and Vascular Biology Scientific Sessions on April 9, 2010 at 5pm (PST) in San Francisco, CA. The poster, entitled "Subcutaneous RB006, a Direct FIXa Inhibitor Provides...

2010-03-16 06:00:00

New Peptide Array Facility Designed to Expedite the Drug Discovery Process VANCOUVER, March 16 /PRNewswire/ - Kinexus Bioinformatics Corporation, a world leader in functional proteomics research, announced the launch of a new peptide synthesis facility to provide researchers with the latest in peptide array technologies. These new services will facilitate and expedite access to peptide platforms for innovative approaches to proteomic research and discovery. A variety of peptide services are...

2010-03-15 08:30:00

BASKING RIDGE, N.J., March 15 /PRNewswire/ -- Regado Biosciences, Inc., a privately held company leading the development of antithrombotic aptamers with active control agents, announced that Chris Rusconi, PhD, Senior Vice President, Chief Scientific Officer and Steven Zelenkofske, DO, FACC, Senior Vice President , Chief Medical Officer presented an abstract at the American College of Cardiology on Monday, March 15, 2010 in Atlanta, Georgia. The poster, entitled "Subcutaneous FIXa...

2010-02-25 09:01:00

ST. LOUIS, Feb. 25 /PRNewswire/ -- Supelco, a division of Sigma-Aldrich® (Nasdaq: SIAL), announced today the launch of Ascentis Express Peptide ES-C18, a high-speed, high-performance liquid chromatography (HPLC) column based on a new 160 angstrom Fused-Core(TM) particle design. This column design exhibits very high column efficiency, providing a stable, reversed phase packing with a pore structure and pore size that is optimized for reversed-phase HPLC separations of...

2010-02-24 11:19:33

Efficient identification of drug candidates The search for new therapeutic agents is time-consuming and expensive. Pharmaceutical companies may have to screen thousands of compounds for the ability to bind a target molecule before they hit upon a promising drug candidate. A group of Biophysicists at LMU Munich led by Professor Dieter Braun, a member of the Cluster of Excellence "Nanosystems Initiative Munich" (NIM), and a partner in NanoTemper (an LMU spin-off), have now developed a unique...


Word of the Day
attercop
  • A spider.
  • Figuratively, a peevish, testy, ill-natured person.
'Attercop' comes from the Old English 'atorcoppe,' where 'atter' means 'poison, venom' and‎ 'cop' means 'spider.' 'Coppa' is a derivative of 'cop,' top, summit, round head, or 'copp,' cup, vessel, which refers to 'the supposed venomous properties of spiders,' says the OED. 'Copp' is still found in the word 'cobweb.'
Related